200 related articles for article (PubMed ID: 2422109)
21. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining.
Kwee WS; Veldhuizen RW; Golding RP; Mullink H; Stam J; Donner R; Boon ME
Virchows Arch A Pathol Anat Histol; 1982; 397(3):287-99. PubMed ID: 6186071
[TBL] [Abstract][Full Text] [Related]
22. Localized fibrous mesothelioma: an immunohistochemical and electron microscopic study.
Said JW; Nash G; Banks-Schlegel S; Sassoon AF; Shintaku IP
Hum Pathol; 1984 May; 15(5):440-3. PubMed ID: 6202620
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
24. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
Corson JM; Pinkus GS
Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295
[TBL] [Abstract][Full Text] [Related]
25. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
26. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
Miettinen M; Limon J; Niezabitowski A; Lasota J
Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
[TBL] [Abstract][Full Text] [Related]
27. Desmoplastic diffuse mesothelioma.
Cantin R; Al-Jabi M; McCaughey WT
Am J Surg Pathol; 1982 Apr; 6(3):215-22. PubMed ID: 7102900
[TBL] [Abstract][Full Text] [Related]
28. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
29. Immunoperoxidase staining of malignant cells in pleural effusions.
Pastormerlo M
Pathologica; 1990; 82(1080):421-5. PubMed ID: 2284143
[TBL] [Abstract][Full Text] [Related]
30. Pleural mesothelioma of connective tissue type, localized fibrous tumour of the pleura, and reactive submesothelial hyperplasia. An immunohistochemical comparison.
Al-Izzi M; Thurlow NP; Corrin B
J Pathol; 1989 May; 158(1):41-4. PubMed ID: 2754539
[TBL] [Abstract][Full Text] [Related]
31. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
Saad RS; Cho P; Liu YL; Silverman JF
Diagn Cytopathol; 2005 Mar; 32(3):156-9. PubMed ID: 15690334
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.
Churg A
Am J Surg Pathol; 1985 May; 9(5):360-5. PubMed ID: 2418692
[TBL] [Abstract][Full Text] [Related]
33. Value of D2-40 in the differential diagnosis of pleural neoplasms with emphasis on its positivity in solitary fibrous tumor.
Hu Y; Yang Q; McMahon LA; Wang HL; Xu H
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):411-3. PubMed ID: 20436345
[TBL] [Abstract][Full Text] [Related]
34. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.
Kortsik CS; Werner P; Freudenberg N; Virchow JC; Kroegel C; Pott M; Matthys H
Lung; 1995; 173(2):79-87. PubMed ID: 7536281
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
Duggan MA; Masters CB; Alexander F
Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
[TBL] [Abstract][Full Text] [Related]
36. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
37. Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma.
Nakashima Y; Inamura K; Ninomiya H; Okumura S; Mun M; Kirimura S; Kobayashi M; Okubo K; Ishikawa Y
Lung Cancer; 2020 Oct; 148():20-27. PubMed ID: 32777673
[TBL] [Abstract][Full Text] [Related]
38. Immunocytology in malignant pleural mesothelioma. Expression of tumor markers and distribution of lymphocyte subsets.
Guzman J; Bross KJ; Würtemberger G; Costabel U
Chest; 1989 Mar; 95(3):590-5. PubMed ID: 2646076
[TBL] [Abstract][Full Text] [Related]
39. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma.
Lucas JG; Tuttle SE
J Surg Oncol; 1987 May; 35(1):30-4. PubMed ID: 2437407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
